Results 41 to 50 of about 6,090,817 (193)

Prognostic indicators for the development of strabismus among patients with graves’ ophthalmopathy

Journal of Clinical & Translational Endocrinology, 2017
Objective: Thyroid eye disease (TED), an autoimmune inflammatory process involving the orbital tissues around the eye, is the most common extra-thyroidal manifestation of Graves’ disease (GD). Due to changes in the patient’s appearance, TED is a socially
Tiffany Y. Lin, Ning Li, Michael W. Yeh, Angela M. Leung, Daniel B. Rootman   +4 more
doaj   +1 more source

PSAT265 Blood Glucose in Thyroid Eye Disease (TED) in Patients treated with Teprotumumab: Clinical Trials Data [PDF]

J Endocr Soc, 2022
Abstract Background Teprotumumab, an FDA-approved insulin-like growth factor-1 receptor inhibitor for TED, improves proptosis, diplopia, inflammation, and quality of life. In the pooled phase 2 and 3 trial analysis, 8/84 (10%) teprotumumab-treated patients reported hyperglycemia adverse events (AEs ...
Smith, Terry J, Bhattacharya, Rajib K, Hsu, Kate, Kim, Sun, Sile, Saba, Barbesino, Giuseppe, Holt, Robert   +6 more
europepmc   +2 more sources

The role of pain in Graves' orbitopathy: Associations with clinical activity and quality of life

Acta Ophthalmologica, EarlyView.
Abstract Purpose Pain is included in the clinical activity score (CAS) as an indicator of inflammatory activity in Graves' orbitopathy (GO), yet its clinical relevance has not been systematically evaluated. We therefore investigated the relationship between pain, other inflammatory signs and quality of life (QoL), and assessed the effect of intravenous
Gijsbert J. Hötte, Willem A. Dik, Ronald O. B. de Keizer, Sodaba Khatab, Marco Medici, Maaike de Bie, P. Martin van Hagen, Dion Paridaens   +7 more
wiley   +1 more source

Case Report: Development of severe inflammatory orbitopathy after immune checkpoint inhibitor initiation

Frontiers in Ophthalmology
We report a case of thyroid eye disease (TED) reactivation, review the literature, and raise awareness of severe ophthalmopathy and myositis following the initiation of cancer treatment with an immune checkpoint inhibitor (ICI).
Samantha Madala, Alomi Parikh, Alomi Parikh, Kendra Hong, Michael Burnstine, Michael Burnstine   +5 more
doaj   +1 more source

The epidemiological characteristics of patients with thyroid eye disease in a referral center in northern Iran

Journal of Current Ophthalmology, 2018
Purpose: This study was conducted to determine the demographics, clinical features, severity, and activity of thyroid eye disease (TED) in patients of a referral center in the north of Iran.
Abdolreza Medghalchi, Mitra Akbari, Yousef Alizadeh, Reza Soltani Moghadam   +3 more
doaj   +1 more source

The Role of the Immune Response in the Pathogenesis of Thyroid Eye Disease: A Reassessment. [PDF]

PLoS ONE, 2015
Although thyroid eye disease is a common complication of Graves' disease, the pathogenesis of the orbital disease is poorly understood. Most authorities implicate the immune response as an important causal factor.
James T Rosenbaum, Dongseok Choi, Amanda Wong, David J Wilson, Hans E Grossniklaus, Christina A Harrington, Roger A Dailey, John D Ng, Eric A Steele, Craig N Czyz, Jill A Foster, David Tse, Chris Alabiad, Sander Dubovy, Prashant K Parekh, Gerald J Harris, Michael Kazim, Payal J Patel, Valerie A White, Peter J Dolman, Deepak P Edward, Hind M Alkatan, Hailah Al Hussain, Dinesh Selva, R Patrick Yeatts, Bobby S Korn, Don O Kikkawa, Patrick Stauffer, Stephen R Planck   +28 more
doaj   +1 more source

A ‘Real Life’ Service Evaluation Model for Multidisciplinary Thyroid Eye Services

Frontiers in Endocrinology, 2021
Background/AimsThere is no universal consensus on the practical implementation and evaluation of the Amsterdam Declaration on Graves Orbitopathy in a Multidisciplinary Thyroid Eye Disease (MDTED) pathway.
Soma Farag, Soma Farag, Claire Feeney, Claire Feeney, Vickie Lee, Vickie Lee, Sonali Nagendran, Rajni Jain, Ahmad Aziz, Ahmad Aziz, Rashmi Akishar, Vassiliki Bravis, Karim Meeran, Karim Meeran   +13 more
doaj   +1 more source

The relation between clinical response and quality of life improvement after treatment with intravenous methylprednisolone in Graves' orbitopathy

Acta Ophthalmologica, EarlyView.
Abstract Background Quality of life (QoL) is a key outcome in Graves' orbitopathy (GO), but prior studies have reported overall QoL changes without evaluating whether improvements occur specifically in patients who achieve objective clinical response.
Gijsbert J. Hötte, Willem A. Dik, Ronald O. B. de Keizer, Sodaba Khatab, M. Medici, Sigrid M. A. Swagemakers, Peter J. van der Spek, P. Martin van Hagen, Dion Paridaens   +8 more
wiley   +1 more source

Periorbital Fat Loss From Prostaglandin Analogues: Dermatologic and Cosmetic Considerations

Journal of Cosmetic Dermatology, Volume 25, Issue 11, November 2026.
ABSTRACT Background Topical prostaglandin (PG) analogues, originally developed as first‐line therapies for glaucoma, are increasingly used in dermatology and cosmetic settings to promote eyelash and eyebrow growth. However, their use has been associated with prostaglandin‐associated periorbitopathy (PAP), a constellation of adverse effects including ...
Lily Kaufman, Aliza Khuhro, Sierra Schwierking, Lilia Valentic, Sonja Kobayashi, Lauren Malley, Olivia Ueltschi, Lucy Rose, Brittany Dulmage   +8 more
wiley   +1 more source

Average muscle volume (mm³) of thyroid eye disease (TED) patients versus normal control patients.

, 2016
Average muscle volume (mm3) of thyroid eye disease (TED) patients versus normal control patients.
In Jeong Lyu (847266), Ju-Yeun Lee (769571), Kunho Bae (845719), Sei Yeul Oh (754088), Kyung-Ah Park (754082)   +4 more
core   +1 more source